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Purpose: The aim of this study is to examine the epidemiologic and economic burden in 
surgically resected localized gastrointestinal stromal tumor (GIST) patients versus age- and 
gender-matched controls.
Method: Two data sources were used to conduct a series of complementary analyses. First, the 
Surveillance, Epidemiology, and End Results (SEER) cancer registry was used to identify 
  diagnosed GIST patients from 1993 to 2002 and determine incidence, prevalence, and 3-year 
survival. Second, using the SEER–Medicare linked database, a matched case-control analysis 
was   conducted to determine resource utilization, GIST recurrence, and costs. Because GIST 
recurrence is not explicitly defined in the database, patterns in resource use were used to identify 
probable recurrence. Kaplan–Meier Sample Average (KMSA) Estimator technique was used to 
estimate costs of GIST and recurrence.
Results: SEER registry results show over the 10-year time horizon average annual GIST 
incidence was 0.32 per 100,000 persons in the United States, 15-year limited-duration prevalence 
was 1.62 per 100,000 persons, and 3-year survival was 73%. A total of 292 GIST patients were 
included in the SEER–Medicare analyses; 35 were identified with probable recurrence. GIST 
patients had increased risk of mortality (hazard ratio: 1.23; 95% confidence intervals: 0.94–1.61) 
compared to controls. Median recurrence-free and postrecurrence survival was 45 and 46 months, 
respectively. GIST patients incurred significantly higher medical care costs in the first year after 
initial resection, with $23,221 attributable to GIST. GIST recurrence costs totaled $101,700 
over 5 years after initial resection.
Conclusions: GIST is associated with substantial medical care costs, estimated recurrence 
costs more than $100,000; treatments that delay or reduce recurrence could substantially reduce 
the burden of GIST.
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Introduction
Gastrointestinal stromal tumors (GIST) grow in the walls of the gastrointestinal tract, 
occurring most often in the stomach, although the small intestine and colon are also 
common sites.1 The incidence of GIST in the United States is estimated to be 3000–4000 
cases per year,2 with the age of majority of the diagnosed patients being in the range 
of 40–80 and a median age of 60 years.3
Localized GIST has historically been treated with a combination of surgery and 
chemotherapy; however, because chemotherapy has since proven ineffective in the 
treatment of GIST, surgical resection is now the primary treatment for resectable 
tumors.4 Although surgical resection is currently the standard of care,5 complete gross 
resection of localized GIST is associated with a 5-year survival of 48%–65%.6–8 International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Poor survival is largely associated with high recurrence rates, 
which are .40% within the first 2 years following surgical 
resection.7 Several prognostic factors have been associated 
with risk of recurrence, including tumor size, location, 
and mitotic index.9–11 Few studies have specifically examined 
the burden of illness for surgically resected localized GIST. 
With the advent of new targeted therapy used in the pre-
vention of GIST recurrence, it is important to understand 
the burden of this disease to quantify the potential benefits 
of these therapies. Therefore, we conducted a retrospective 
database analysis to examine resource utilization, recurrence, 
survival, and costs in surgically resected localized GIST 
patients.
Methods
A retrospective database analysis was conducted using data 
from the Surveillance, Epidemiology and End Results 
(SEER registry of the National Cancer Institute and the 
SEER–Medicare linked database to assess the epidemiologic 
and economic burden of surgically resected localized GIST. 
The SEER registry was used to estimate incidence, prevalence, 
and 3-year survival; the SEER–Medicare linked data were 
used to estimate survival, recurrence-free survival (RFS), 
resource utilization, and medical care costs.
seeR registry analyses
The SEER registry is a surveillance system that collects 
information on all newly diagnosed cancer cases in specified 
geographic areas. SEER Stat software (National Cancer 
Institute, Bethesda, MD) estimates incidence, prevalence, 
and survival directly by standardizing estimates to the US 
population and was used for analyses.
sample selection
Patients included all those diagnosed with GIST between 
1993 and 2002. Because the specific histology code identify-
ing GIST (ICD-O-3 8936/3) was not introduced until 2001, 
an algorithm previously validated by Tran and colleagues12 
along with the GIST histology code, where available, was 
used to identify GIST cases prior to 2001. Patients were 
categorized as having localized and resected GIST based on 
SEER Stat variables that identify cancer stage and surgery 
of the primary tumor site.
study measures
Incidence was calculated as the number of new GIST cases 
per 100,000 population stratified by age group, gender, race, 
and tumor size. Cancer prevalence was defined as the number 
of individuals currently alive who have been diagnosed with 
cancer at any point in time, irrespective of time since   diagnosis, 
current treatment, or cure. Limited-duration prevalence 
represents the proportion of people alive on a certain day who 
had a diagnosis of the disease within a specified time frame. 
According to SEER, registries of shorter duration, ,40 or 
50 years of data collection, can only estimate limited-duration 
prevalence. This analysis estimates 15-year limited-duration 
prevalence, which was calculated based on the number 
of patients diagnosed with GIST and alive on the first day of 
the year during the 15 years prior to any given year in the 
present study (ie, 1993–2002). Three-year survival was 
defined as the proportion of patients alive 3 years after a GIST 
diagnosis.
seeR–Medicare analyses
The seeR–Medicare database
The SEER–Medicare database is a collaborative effort of the 
National Cancer Institute, the SEER registries, and the   Centers 
for Medicare and Medicaid Services. SEER–Medicare data 
are considered to be a limited-identifiable data set by the 
Health Insurance Portability and Accountability Act   guidelines. 
Consequently, institutional review board approval was not 
required to obtain access to the data.
SEER–Medicare claims were used to identify resource 
utilization, survival, and differences in survival by tumor 
size and recurrence among GIST patients. In addition, medi-
cal care costs in the first year after surgical resection of the 
primary GIST diagnosis (initial resection) as well as the 
5-year cumulative costs postinitial resection were estimated 
using the SEER–Medicare data. In addition, algorithms were 
used to identify an increased level of health care activity that 
could signify recurrence, allowing us to infer recurrence-free 
and postrecurrence survival (PRS), and recurrence costs.
Patient selection
Localized GIST cases were selected using the same diagnostic 
algorithm described in the SEER registry section. Patients 
were further limited to those aged above 65 years with continu-
ous Medicare enrollment from 1 year prior to diagnosis through 
the end of the study period or death, whichever is earlier.
The SEER data used to identify surgical resection do have 
a corresponding date of surgery included in the database. 
Therefore, to obtain the date of surgical resection, we used 
the SEER–Medicare database to identify the surgical proce-
dure and assign a date of service. Surgical resection was 
identified as an ICD-9 or CPT surgery procedure code 
(Table 1) appearing in the inpatient or outpatient records or International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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a HCPCS surgery procedure code appearing in the inpatient 
records, from 30 days before to 90 days after the GIST diag-
nosis date. The surgical resection date was set equal to the 
procedure date where available. However, if the SEER vari-
able indicated surgical resection and there was no correspond-
ing procedure code present, then the date of resection was 
set equal to the GIST diagnosis date. The date of surgical 
resection was defined as the ‘index date’.
Patients were excluded if they met any of the following 
criteria: any other cancer diagnosis prior to their index date, 
not eligible for Medicare Part A or B benefits starting 
12 months before GIST diagnosis through follow-up, 
enrolled in health maintenance organization starting 
12 months before GIST diagnosis through follow-up, Medi-
care eligibility based on end-stage renal disease or disability, 
date of death unknown or disparate by 3 months or more 
between SEER and Medicare, or first GIST diagnosis at time 
of death or autopsy.
An age- and gender-matched control cohort of cancer-free 
patients was selected from Medicare enrollment files using 
the 5% sample of Medicare beneficiaries residing in SEER 
geographic areas. Control patients were not required to have 
used services and were not excluded if they developed 
  non-GIST cancers after their index date. Control patients 
were excluded if they met any of the applicable exclusions 
for cases. Control patients were matched 1:1 with GIST 
patients on age and gender and assigned the same index date. 
After applying the study inclusion/exclusion criteria, the final 
GIST cohort was limited to those with localized disease.
study measures
Gender and race were derived directly from SEER–Medicare, 
and race was categorized as white, black, other, and unknown 
(if values are missing). An adapted version of the Charlson 
comorbidity index13,14 was calculated using preindex date 
patient records, and chronic malignancy was excluded as a 
comorbidity. Length of Medicare follow-up (in months) was 
calculated by dividing the number of days between index and 
end dates by 30.25. The end date was the date of death or the 
end of Medicare claims (ie, December 31, 2005). Resource 
utilization per person-year was calculated by dividing the 
total resource use between index and end dates by total fol-
low-up time in years. Number of hospital days reflected the 
number of days between admission and discharge, with both 
the admission and discharge dates inclusive and excluded 
hospice institutions and home health agencies.
For significance testing, the Student’s t-test was used for 
continuous variables and the χ2 test with categorical   variables. 
An alpha level of 0.05 was used for all tests. All analyses 
were conducted using SAS version 9.1 (SAS Institute Inc, 
Cary, NC).
Cancer recurrence is not explicitly identified in the 
SEER–Medicare database; therefore, we constructed an 
algorithm which looks for additional surgical resections or 
other surgical procedures or gaps in chemotherapy treatment 
as a proxy for recurrence. Patients that satisfied at least one 
of the following criteria were considered to have a recurrence: 
surgical resection at least 90 days after the index date, radiof-
requency ablation (CPT 43258, ICD-9 44.44) or embolization 
(CPT 61624, ICD-9 45.43, 42.33) at least 90 days after the 
index date, initial indication of chemotherapy treatment at 
least 90 days after the index date, or a gap in chemotherapy 
treatment of at least 90 days.
Median survival, RFS, and PRS were assessed using 
Kaplan–Meier analyses; differences between cases and con-
trols were assessed using Cox proportional hazards   models 
controlling for age, gender, income, and urban area. Survival 
was estimated from the index date until death. RFS was 
Table 1 Administrative codes used to identify surgical resection of GIsT
Surgery site Administrative codes (CPT, ICD-9, HCPCS)
esophagus CPT: 43100–43101, 43105, 43106, 43115, 43116, 43122, 43124, 34360, 43216–43217
ICD-9: 42.3, 42.32, 42.33, 42.25, 42.41
stomach CPT: 43610–43611, 43250–43251, 43258
ICD-9: 43.4, 43.41, 43.42, 44.15
small intestine CPT: 44110–44111, 44120–44121, 44125, 44130, 44202–44203, 44364–44365, 44369
ICD-9: 45.3, 45.33, 45.6, 45.90–45.93, 45.95, 45.62, 45.6, 45.30, 45.31, 45.15
colon, rectum, and anus CPT: 44392–44394, 45308–45309, 45315, 45383–45385, 45160, 45170, 44140–44147, 44160, 
44204–44208, 45113–45116, 45123, 45180, 45310, 45336, 45338, 45339, 46610, 46611, 46612
ICD-9: 48.35, 48.3, 48.5, 45.41, 45.42, 45.94, 45.95,
Peritoneum, omentum, and mesentery CPT: 49200, 49201
ICD-9: 54.4, 54.3, 54.22, 54.23
Any site HCPCS: s2095, D7440–D7441, D7450–D7451, D7460–D7461, D7465, D7413–D7415
Abbreviations: CPT, current procedure terminology; ICD, international classification of diseases; HCPCS, healthcare common procedure coding system.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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e  stimated from the index date until recurrence or death, and 
PRS was estimated from the date of recurrence until death. 
Patients with follow-up data ending before recurrence or death 
were censored, and the number of months spent alive was 
calculated as the difference between their last date of follow-up 
and the index date divided by 30.25. Differences in survival 
and RFS stratified by tumor size were also assessed using Cox 
proportional hazards models controlling for the same demo-
graphic characteristics as in the case-control analysis.
Health care costs in the first year after initial resection 
and 5-year cumulative costs were calculated using the KMSA 
estimator,15 a technique that accounts for variable follow-up 
due to death or censoring, and thereby provides an unbiased 
estimate of the average costs. Data were partitioned into 
30-day intervals, where each month’s average cost was mul-
tiplied by the probability of surviving to the start of the 
month; the survival-adjusted costs were then summed to 
produce the total expected costs for the first year and over 
the 5-year period following initial resection. The total GIST-
attributable costs were estimated as the difference in total 
costs between cases and controls. Costs attributable to GIST 
recurrence were estimated as the difference between costs 
among GIST patients with a recurrence (cases) and those 
GIST patients without a recurrence (controls).
Costs were estimated for each resource utilization cate-
gory and reported overall and by tumor size. Bootstrapping 
methods (sampling with replacement) were used to obtain 
95% credible intervals (95% confidence intervals [CI]) for 
the KMSA analyses.
Fewer recurrences were identified in our analyses (12% 
over the entire study period) compared with published recur-
rence rates (32%–40%).7,16 Therefore, we performed one-way 
sensitivity analyses using different algorithms to identify 
recurrence. First, we shortened the time interval between 
initial surgical resection and detection of a recurrence from 
90 to 60 days using the original surgical procedures to iden-
tify recurrence. Second, keeping the days between the index 
date and identification of a recurrence fixed at 90 days, 
we added the following: 1) additional procedure/HCPCS 
codes for biopsy (32405), excision (11642, 22900, 49201), 
radiation (77413, 77300), chemotherapy (96408, 96410–
96412, 96549, Q0085), and other surgical procedures (88172, 
88305, 43235, 43239); 2) a surgical procedure coupled with 
an ICD-9 cancer diagnosis (140–239 excluding benign 
tumors) on the same date; and 3) identification of inpatient 
hospitalization with an ICD-9 cancer diagnosis (140–239 
excluding benign tumors).
Results
seeR registry results
Incidence, prevalence, and 3-year overall survival are 
displayed in Table 2. Between 1993 and 2002, 1466 new 
cases of surgically resected localized GIST were identified 
in the SEER database. The average annual incidence was 
0.32 per 100,000, and the average annual 15-year preva-
lence was 1.62 per 100,000. The average 3-year survival 
for GIST cases that were diagnosed between 1993 and 
2002 was 73%.
seeR–Medicare results
From an initial sample of 1725 GIST patients, we identified 
292 patients newly diagnosed with GIST between 1993 
and 2002 who met all of the inclusion criteria (Figure 1). 
The final sample consisted of these 292 GIST patients with 
Table  2  Incidence,  prevalence  and  3-year  survival  for  GIsT 
patients from the seeR registry
Incidence/ 
100,000
Prevalence/ 
100,000
3-year  
survival
Overall  
Age (years):
0.32 1.62 73%
,5 0.06 0.24 86%
05–14 0.01 0.28 100%
15–24 0.03 0.17 81%
25–34 0.06 0.33 83%
35–44 0.18 0.94 86%
45–54 0.40 2.05 84%
55–64 0.80 3.87 70%
65–74 1.10 5.38 72%
75–84 1.47 7.81 61%
85+ 0.94 7.50 49%
Sex:
Male 0.34 1.44 70%
Female 0.31 1.80 75%
Race:
White 0.29 1.59 73%
Black 0.50 1.45 65%
Other 0.43 2.01 76%
Hispanic ethnicity:
non-spanish- 
hispanic-Latino
0.33 n/A 72%
spanish- 
hispanic-Latino
0.29 n/A 75%
Tumor size (cm):
0–,3 0.02 0.10 76%
3–,6 0.07 0.32 77%
6–10 0.10 0.41 77%
.10 0.10 0.38 66%
Unknown 0.02 0.11 67%
Note: GIST identification based on Tran algorithm or the ICD-O-3 GIST code (8936). 
Prevalence was not available for those of hispanic origin.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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an equal number of age- and gender-matched controls; 
35 GIST cases experienced a GIST recurrence during the 
10-year follow-up. Out of the 292 GIST patients, 15 presented 
with tumors ,3 cm, 73 with tumors 3 to ,6 cm, 86 with 
tumors 6 to ,10 cm, 99 with tumors $10 cm, and the remain-
ing 19 patients had unknown tumor size.
Table 3 presents the patient characteristics for the 
GIST cohort and their matched controls. There were no 
statistically significant differences found for age, gender, 
geographic region, location of residence, or median 
income, but there were significantly more white controls 
than cases. The   Charlson comorbidity index score was 
significantly higher for cases than controls, and signifi-
cantly longer Medicare follow-up was seen for controls 
than cases.
GIST cases experienced significantly more hospital stays 
and hospital days than their matched controls. Mean annual 
hospitalization for cases was 1.6 and 0.7 for controls 
(P , 0.001); mean number of days were 13.8 for cases and 
6.0 for controls (P , 0.001).
Figure 2 displays the Kaplan–Meier survival curves for 
GIST cases and their matched controls. Median overall 
survival for cases was 58.7 months and 74.7 months for 
controls. When controlling for age, gender, income, and 
urban area, the mortality hazard ratio for cases relative to 
controls is 1.23 (95% CI: 0.94–1.61). Median survival for 
patients with tumors 3 to ,6 cm was 87.6 months, 
6 to ,10 cm was 74 months, $10 cm was 50 months, and 
unknown tumor size was 42.8 months. The median survival 
could not be estimated for tumor sizes ,3 cm due to small 
numbers of events. When controlling for age, gender, income, 
and urban area, survival did not significantly differ by tumor 
size (P = 0.117).
The median RFS for GIST cases was 44.9 months. When 
stratifying by tumor size, RFS was lowest among patients 
with tumors ,3 cm (32.3 months) and tumors $10 cm 
(35.7 months) and higher for patients with tumors 3 to ,6 cm 
(87 months) and tumors 6 and ,10 cm (46.5 months) 
(Table 4). Controlling for age, gender, income, and urban 
area, RFS did not significantly differ by tumor size for 
tumors .3 cm (P = 0.08). Median PRS was estimated 
at 46.3 months for all tumor size; for those with tumors 
3 to ,6 cm, it was 11.8 months, and for those with 
tumors $10 cm, it was 35.4 months.
Total costs in the first year after initial resection 
were ∼$23,200 (95% CI: $16,600–$30,600) higher for cases 
than controls ($35,500 vs $12,300) (Figure 3). Costs by 
resource utilization category are presented in Table 5. GIST-
related hospital costs accounted for the majority of the total 
costs and were estimated to be $16,900 (95% CI: $13,500–
$20,500); outpatient costs were $4250 (95% CI: $55.9–
$9580). When stratifying by tumor size, patients with tumors 
3 to ,6 cm had the largest GIST-attributable costs ($28,200) 
compared to those with tumors ,3 cm ($2650) or 6 to ,10 cm 
1,725 Starting
sample size
422 excluded
age <65 years
171 excluded
no valid GIST
diagnosis
226 excluded
no initial surgical
resection
292 age and sex
matched controls
selected
Localized resected
GIST = 292
32 excluded
disability and/or
renal disease
251 excluded
no Medicare HMO
coverage
55 excluded
no coverage both
Parts A and B
Figure 1 seeR–Medicare analysis sample selection.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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($21,800) or $10 cm ($23,900). Cost d  ifferences between 
cases and controls were significant for all tumor groups, 
except those with tumors ,3 cm ($2650, 95% CI: $19,800–
$28,300). Finally, GIST-related hospital costs ranged 
from $6630 (95% CI: $6590–$24,100) for patients with 
tumors ,3 cm to $18,100 (95% CI: $9890–$25,500) for 
patients with tumors 3 to ,6 cm.
The 5-year cumulative costs were ∼$24,800 (95% 
CI: $3140–$55,200) higher for cases than controls ($98,900 
vs $74,100). GIST-related hospital costs were estimated to 
be $14,100 (95% CI: $4930–$23,200), and outpatient costs 
were $12,700 (95% CI: $8390–$37,400). When stratifying 
by tumor size, the 5-year cumulative costs are significantly 
higher for individuals with tumors between 3 and 6 cm 
compared to their controls ($107,500, 95% CI: $4790–
$251,500). GIST-related hospital costs ranged from $10,200 
(95% CI: $30,500–$12,700) for patients with tumors ,3 cm 
to $27,400 (95% CI: $11,200–$48,600) for patients with 
tumors 3 to ,6 cm.
Five-year cumulative costs for patients without a recur-
rence were estimated to be $83,400; those with a recurrence 
incurred costs of $185,100. These results indicate that GIST 
recurrence adds an additional $101,700 (95% CI: $8840–
$219,200) to the cost of care over the 5-year period after 
initial surgical resection (Figure 4).
sensitivity analyses
The first sensitivity analysis, shortening the gap days 
between services to 60 days, identified 10 additional GIST 
cases with recurrence (45); when these patients were 
included in the analysis, median PRS increased to 
70.2 months and costs attributable to recurrence over the 
Table 3 Overall patient characteristics and demographics for GIsT patients and their matched controls in seeR-Medicine
Characteristic All GIST 
patients 1993–2002
Matched controls Difference  
(cases-controls)
p-value*
Number of patients 292 292 0 n/A
Age as of initial GIST diagnosis:
Mean (SD) 76 (6.4) n/A n/A n/A n/A
Median 75 n/A n/A n/A
Interquartile range 65 91 n/A n/A n/A n/A
Age as of initial GIST diagnosis (n[%]):
65–74 years 130 (44.5) n/A n/A n/A n/A
75–84 years 133 (45.6) n/A n/A n/A n/A n/A
85+ years 29 (9.9) n/A n/A n/A n/A
Male (n, %) 125 (42.8) n/A n/A n/A n/A n/A
Race (n, %):
caucasian 215 (73.6) 258 (88.4) -43 -(14.7)
Black 33 (11.3) 19 (6.5) 14 (4.8) ,0001
Other 44 (15.1) 15 (5.1) 29 (9.9)
Charlson comorbidity index:
Mean (SD) 1.6 (2.0) 1.2 (2.0) 0.4 (0.0) 0.037
Median 1.0 1.0 0.0
Interquartile range 0.0 11.0 0.0 10.0 0.0 1.0
Geographic region (n, %):
northeast 42 (14.4) 44 (15.1) -2 -(0.7)
Midwest 74 (25.3) 82 (28.1) -8 -(2.7)
0.8115
south 23 (7.9) 19 (6.5) 4 (1.4)
West 153 (52.4) 147 (50.3) 6 (2.1)
Median household income by zip code (n, %):
Less than $39,999 122 (42.0) 119 (41.0) 3 (1.0)
$40,000–$79,999 153 (52.0) 148 (51.0) 5 (1.0) 0.439
Greater or equal to $80,000 17 (6.0) 25 (8.0) -8 (-2)
Length of Medicare follow-up (months):
Mean (SD) 33.3 (29.8) 39.2 (32.0) -5.9 -(2.3) 0.022
Median 25.2 30.6 -5.4
Interquartile range 0.1 119.7 0.3 119.7 -0.2 0.0International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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5-year period after surgical resection also increased. 
The 5-year recurrence-attributable cumulative costs were 
$161,700 (95% CI: $66,100–$276,300). The second sen-
sitivity analysis (with additional procedure codes) identi-
fied 104 additional GIST cases with recurrence (139). With 
the inclusion of these additional patients in the analyses, 
median PRS decreased to 28 months, and 5-year recurrence 
costs also decreased. Cumulative 5-year costs attributable 
to recurrence were $89,100 (95% CI: $51,100–$131,200) 
over the 5-year period after initial surgical resection in this 
analysis.
Discussion
A retrospective database analysis was conducted to examine 
the epidemiologic and economic burden of GIST. The results 
showed that localized resected GIST affects ∼1000 people 
each year, and the burden of GIST recurrence is a major 
driver of the economic impact of disease. GIST-attributable 
costs in the first year after surgical resection were estimated 
to be $23,300. The 5-year GIST-attributable cumulative costs 
were estimated to be $24,800. These results indicate that 
the majority of GIST-attributable costs are accrued in the 
first year of disease. In addition, $16,900 (73%) of the 
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Figure 2 Overall survival for GIsT patients and their matched controls.
Table 4 Recurrence-free survival estimates
Characteristic Tumor size
0-,3 cm 3-,6 cm 6-,10 cm $10 cm unknown
Number of patients 15 73 86 99 19
Number of patients with recurrence 1 6 11 14 3
Recurrence-free survival (months)
Median 32.3 87.0 46.5 35.7 17.6
Interquartile range (25–75) (18.6–N/A) (25.6–N/A) (27.4–N/A) (13.8–72.2) (3.9–62.7)International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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GIST-attributable costs in the first year were related to the 
hospital, indicating that the majority of costs in the first year 
are likely related to surgical resection as treatment for the 
disease. The 5-year cumulative cost for GIST patients with 
a recurrence was estimated to be almost twice as much as 
the cost for GIST patients without a recurrence ($185,100 
vs $83,400), respectively.
We were not able to identify any other published studies 
that examine costs accrued by patients with GIST after initial 
surgical resection. However, similar methodology was used 
in another study assessing costs of recurrence in breast cancer 
patients. Stokes et al17 used SEER–Medicare data to estimate 
breast cancer recurrence costs and survival. Their study 
reported substantial increases in costs due to breast cancer 
recurrence. To our knowledge, our study is the first study to 
examine GIST-attributable costs and costs related to GIST 
recurrence. The results of this study may be useful to indi-
viduals conducting economic assessments of GIST 
treatments.
Any interpretations of the findings from the present 
study are subject to several limitations. The SEER registry 
data represent about 30% of the US population; therefore, 
results may not be representative of all GIST patients. 
Although a validated algorithm was used to identify GIST 
patients before 2001, grouping stromal tumors may inad-
vertently include diseases other than GIST.18 Also certain 
groups are under or overrepresented in SEER data (eg, black 
and ‘other’ races).19
The Medicare database does not directly identify a cancer 
recurrence. We used an algorithm that looks for additional 
surgical resections, procedures, or gaps in chemotherapy 
treatment as a proxy for recurrence. We performed sensitivity 
analyses around identification of recurrence; however, the 
sensitivity and specificity of the algorithm to appropriately 
identify recurrences is unknown. Published literature sug-
gests that ∼40% of patients with localized disease experience 
a recurrence,7 whereas only 12% of GIST patients in our 
study were identified as having a recurrence, suggesting 
that our main algorithm may have underestimated GIST 
recurrence. In our two sensitivity analyses, the recurrence 
rates were 15% and 48%.
Further limitations result from using Medicare claims 
data to estimate utilization, costs, and recurrence because the 
population is restricted to patients aged 65 years and older. 
Consequently, our results may not be applicable to the entire 
localized GIST population whose mean age is 63 years.12 We 
acknowledge that because higher medical costs are accrued 
by older than younger patients (ie, $65 vs ,65 years old), 
cost differences between cases and controls would be 
expected to be greater for patients ,65 years old. Using data 
restricted to persons $65 years of age may also impact our 
estimates of survival. Because our population is elderly, 
a large portion of the sample is likely dying of causes other 
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Figure 3 GIST attributable cost first-year after initial resection.
Table 5 First-year medical costs by resource utilization category 
for GIsT patients and their matched controls in seeR-Medicare
GIST 
cases
Matched 
controls
Difference 
(cases-controls)
hospital $22,042 $5,173 $16,900
Outpatient $8,369 $4,121 $4,200
hospice $66 $367 -$300
home health $1,265 $611 $700
skilled nursing facility $1,426 $246 $1,200
Physician $1,804 $1,488 $300
Durable medical equipment $506 $251 $300International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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than GIST; this may complicate the interpretation of survival 
differences between cases and controls, especially when 
analyzing survival over a long period of time (5 years). 
In addition, SEER–Medicare data do not include some 
healthcare services, such as oral prescription medications, 
which could pose another limitation, except that oral medica-
tions were not used in the treatment of localized GIST during 
this time period and would likely not affect our findings. 
Finally, costs were evaluated from a limited perspective 
(ie, Medicare-covered patients only), although because 
Medicare is a primary payer for older patients, we expect 
that the bulk of costs were captured in our analysis.
Our findings provide an increased understanding of the 
burden of localized GIST and suggest that recurrence 
  contributes substantially to the economic impact of GIST. 
In light of these results, delaying or preventing recurrence 
should be a priority in treating GIST patients. Presently, the 
only known way to delay or prevent GIST recurrence after 
surgical resection is the use of a tyrosine kinase inhibitor. 
Imatinib (Gleevec/Glivec; Novartis, Basel, Switzerland), 
a tyrosine kinase inhibitor that targets the KIT protein, is 
currently approved by the US Food and Drug Administration 
as adjuvant therapy in surgically resected Kit (CD117)-
positive GIST patients. Our analysis may be under or over-
estimating the burden of the disease given the current use of 
imatinib as adjuvant treatment. The economic impact of such 
treatment is yet to be determined.
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